JAMA jam!

I don't normally quote verbatim, but from 27 March 2009 Science, page 1653:

(OVER)DUE DILIGENCE. The Journal of the American Medical Association (JAMA) this month admitted to having overlooked an author's conflict of interest days after a tense exchange between a journal editor and two academics who had publicized the matter.The paper in question, by psychiatrist Robert Robinson of the University of Iowa and his colleagues, reported that the antidepressant Lexapro could prevent depression in stroke patients if given soon after a stroke. The paper was published in May 2008, and last fall Jonathan Leo of Lincoln Memorial University in Harrogate, Tennessee, and Jeffrey Lacasse of Arizona State University, West, say they "just stumbled on a disclosure" in a previous paper in which Robinson reported that he had been a paid speaker for Forest Pharmaceuticals, which makes the drug. Leo notified JAMA in October, and editors told him they "would look into it." On 5 March, after no further word from JAMA, Leo and Lacasse criticized the paper--and the nondisclosure--in a letter in the British Medical Journal.
Publicizing the case ticked off JAMA's top brass. As first reported in the Wall Street Journal's Health blog, Leo says JAMA Executive Deputy Editor Phil Fontanarosa called him and said, "You are banned from JAMA for life." JAMA Editor-in-Chief Catherine DeAngelis acknowledges that Fontanarosa called Leo to say that "what he was doing was quite unprofessional." But DeAngelis says Fontanarosa actually told Leo that "we certainly don't expect to receive anything from you to be published." On 11 March, JAMA published a letter from Robinson and his co-authors acknowledging the conflict. (Emphasis mine)

UNBELIEVABLE.